Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Marrow sets out to challenge genetic medicines for severe blood diseases

BioPharma DiveView source article

Part of story

Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell

Startup Marrow Therapeutics raised $173 million to develop an siRNA-based infusion therapy for sickle cell disease and beta thalassemia, positioning it as a more accessible alternative to approved one-time CRISPR and gene therapy treatments.

Nov 17, 2026·3 sourcesBiotech innovationGene therapyDrug developmentHematologyBiotechnologyBiotech startupGenetic disordersVenture capital funding
Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell
00

Other sources for this story

STAT News

With $173 million, new startup takes aim at sickle cell

Endpoints

Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell